Alkomex Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 08-07-2024
- Paid Up Capital ₹ 0.10 M
as on 08-07-2024
- Company Age 7 Year, 8 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 6.90 Cr
as on 08-07-2024
- Revenue 0.99%
(FY 2022)
- Profit 7.66%
(FY 2022)
- Ebitda -66.83%
(FY 2022)
- Net Worth 75.81%
(FY 2022)
- Total Assets 27.90%
(FY 2022)
About Alkomex Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹6.90 Cr.
Raghav Mittal, Leena Mittal, and Piyush Mittal serve as directors at the Company.
- CIN/LLPIN
U24303DL2017PTC315829
- Company No.
315829
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
10 Apr 2017
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
East Delhi, Delhi, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Alkomex Pharma?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Raghav Mittal  | Director | 18-Feb-2020 | Current |
| Leena Mittal | Director | 10-Apr-2017 | Current |
| Piyush Mittal | Director | 10-Apr-2017 | Current |
Financial Performance and Corporate Structure Insights of Alkomex Pharma.
Alkomex Pharma Private Limited, for the financial year ended 2022, experienced modest growth in revenue, with a 0.99% increase. The company also saw a slight improvement in profitability, with a 7.66% increase in profit. The company's net worth Soared by an impressive increase of 75.81%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Alkomex Pharma?
In 2021, Alkomex Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
N.G. Electro Products Private LimitedActive 18 years 4 monthsRaghav Mittal, Leena Mittal and 1 more are mutual person
Flurry Foods Private LimitedActive 17 years 11 monthsRaghav Mittal and Piyush Mittal are mutual person
- Vayu Special Chem Private LimitedActive 11 months 15 days
Raghav Mittal and Piyush Mittal are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 25 Jan 2022 | ₹6.90 Cr | Open |
How Many Employees Work at Alkomex Pharma?
Alkomex Pharma has a workforce of 9 employees as of Apr 05, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Alkomex Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Alkomex Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
